Early removal of ovaries may be linked to small increase in risk of Parkinson’s disease in later life
https://www.facingourrisk.org/XRAY/oophorectomy-and-Parkinson-risk
Full article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797712
The lifetime risk of developing Parkinson’s disease is low. However, having surgery to remove both ovaries before natural menopause can slightly increase the risk of Parkinson's disease later in life. Researchers studied over 20 years of medical records, which confirmed this small increase in risk, particularly for women who have their ovaries removed before age 43. (Posted 5/3/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What is my risk of developing ovarian cancer?
- Do you recommend that I get my ovaries removed before menopause; if so, at what age?
- What is my risk of developing Parkinson's disease now? How will my risk change if I have this surgery?
- If I have surgery, can I have estrogen replacement therapy? What are the benefits and risks?
- Are there other things I can do to reduce my risk of ovarian cancer?
Open Clinical Trials
The following are studies looking at ovarian cancer screening or prevention.
- NCT04251052: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk). This study is looking at whether women with BRCA1 mutations who remove just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as women who remove their ovaries and fallopian tubes.
- NCT05287451: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study will look at outcomes in women with BRCA1, BRCA2, BRIP1, RAD51C and RAD51D who remove their fallopian tubes, followed by removal of their ovaries compared to women who undergo standard-of-care removal of their ovaries and fallopian tubes at the same time.
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of MiDe is to develop a test to detect early-onset ovarian cancer. Currently, no reliable screening or early detection tests are available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. These samples can be collected by mobile phlebotomy all around the US.
- NCT04794322: Developing a Test for the Detection of Ovarian Cancer. This study aims to develop an ovarian cancer early detection test that looks at DNA found in a uterine (womb) washing and proteins found in the blood. Participants will not receive the results of their tests.
Additional clinical trials for ovarian cancer screening and prevention may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.